Evotec Se (EVO)

$3.00 -0.06 (-1.96%)
Market Cap 1.09B
Revenue (ttm) 891.97M
Net Income (ttm) -117.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13.13%
Debt to Equity Ratio 0.00
Volume 115,800
Avg Vol 118,960
Day's Range N/A - N/A
Shares Out 355.49M
Stochastic %K 17%
Beta 1.96
Analysts Sell
Price Target $4.67

Company Profile

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 49 40 560 81 0
Address:
Essener Bogen 7, Hamburg, Germany
peloswing
peloswing May. 13 at 1:27 PM
$EVO -12% in pre-market following €116.1 Million Convertible Bond headline 🔻
0 · Reply
KOWALSK1
KOWALSK1 Apr. 20 at 6:56 PM
$EVO
0 · Reply
AnonMav
AnonMav Apr. 17 at 3:11 PM
$EVO Reclaim story begins
0 · Reply
KOWALSK1
KOWALSK1 Apr. 16 at 10:50 PM
$EVO
0 · Reply
BioTuesdays
BioTuesdays Apr. 15 at 2:53 PM
$EVO has appointed Dr. Ingrid Müller as Chief Operating Officer (COO), effective May 1, 2026. https://biotuesdays.com/2026/04/15/dr-ingrid-muller-joins-evotec-as-coo/
0 · Reply
LewisDaKat
LewisDaKat Apr. 15 at 10:31 AM
$EVO Evotec Appoints Dr. Ingrid M ller as Chief Operating Officer https://marketwirenews.com/stock/evo/news/evotec-appoints-dr-ingrid-m-xfc-ller-as-chief-operat-6497978197933043.html?utm_source=stocktwits
0 · Reply
AnonMav
AnonMav Apr. 14 at 9:56 AM
$EVO 1st sign of life 👍
0 · Reply
AnonMav
AnonMav Apr. 12 at 1:47 AM
$EVO Six levels painted. You're at the bottom of the structure, grinding on purple. Below $2.52 = pain. Above $2.95 = first sign of life. Everything above $3.28 is a reclaim story. Don't hold your breath but keep it on the radar. 🤙 https://share.trendspider.com/chart/EVO/94993v3s3vk?_go=anonmav
0 · Reply
investmentstarry
investmentstarry Apr. 2 at 8:45 AM
$EVO — Capital Allocation Update 💡 Board proposes ZERO dividend for 2025 Company pivoting toward share buybacks I like this move — better capital allocation while valuation remains low (PE ~10x)
0 · Reply
BioTuesdays
BioTuesdays Apr. 1 at 2:55 PM
$EVO has appointed Dr. Ashiq H. Khan as EVP global head, chief commercial officer (CCO). https://biotuesdays.com/2026/04/01/evotec-appoints-dr-ashiq-h-khan-as-cco/
0 · Reply
Latest News on EVO
Evotec SE (EVO) Issues €116.1M Convertible Bonds to Support Project Horizon

2026-05-12T23:56:41.000Z - 13 hours ago

Evotec SE (EVO) Issues €116.1M Convertible Bonds to Support Project Horizon

Evotec SE Successfully Placed €116.1 Million Convertible Bonds

Tue, 12 May 2026 17:15:00 -0400 - 16 hours ago

Evotec SE Successfully Placed €116.1 Million Convertible Bonds

EQS-Adhoc: Evotec SE launches approximately EUR 125 million convertible bond offering

2026-05-12T15:45:53.000Z - 21 hours ago

EQS-Adhoc: Evotec SE launches approximately EUR 125 million convertible bond offering

Q1 2026 Evotec SE Earnings Call Transcript

2026-05-07T05:09:52.000Z - 6 days ago

Q1 2026 Evotec SE Earnings Call Transcript

EQS-DD: Evotec SE: Paul Hitchin, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system.

2026-05-05T11:45:04.000Z - 8 days ago

EQS-DD: Evotec SE: Paul Hitchin, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system.

EQS-DD: Evotec SE: Aurélie Dalbiez, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system.

2026-05-05T11:43:47.000Z - 8 days ago

EQS-DD: Evotec SE: Aurélie Dalbiez, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system.

EQS-DD: Evotec SE: Dr. Christian Wojczewski, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system.

2026-05-05T11:41:04.000Z - 8 days ago

EQS-DD: Evotec SE: Dr. Christian Wojczewski, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system.

EQS-DD: Evotec SE: Dr. Cord Dohrmann, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system.

2026-05-05T11:39:02.000Z - 8 days ago

EQS-DD: Evotec SE: Dr. Cord Dohrmann, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system.

EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

2026-05-05T08:57:33.000Z - 8 days ago

EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Evotec (EVO) Advances Preclinical Development Candidate in Dermatology

2026-05-04T11:26:13.000Z - 9 days ago

Evotec (EVO) Advances Preclinical Development Candidate in Dermatology

Evotec nominates first preclinical development candidate from Almirall pact

2026-05-04T10:15:31.000Z - 9 days ago

Evotec nominates first preclinical development candidate from Almirall pact

Evotec SE: Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

2026-05-04T06:02:00.000Z - 9 days ago

Evotec SE: Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

May 4, 2026, 1:50 AM EDT - 9 days ago

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

EVO

Evotec (EVO) Secures Funds from Gates Foundation for TB Drug Development

2026-04-30T10:25:24.000Z - 13 days ago

Evotec (EVO) Secures Funds from Gates Foundation for TB Drug Development

Evotec receives two grants for tuberculosis drug discovery, translation

2026-04-30T09:15:56.000Z - 13 days ago

Evotec receives two grants for tuberculosis drug discovery, translation

Evotec SE: Evotec Receives Grants to Advance Tuberculosis Treatment

2026-04-30T07:26:00.000Z - 13 days ago

Evotec SE: Evotec Receives Grants to Advance Tuberculosis Treatment

Evotec Receives Grants to Advance Tuberculosis Treatment

Apr 30, 2026, 3:20 AM EDT - 13 days ago

Evotec Receives Grants to Advance Tuberculosis Treatment

EVO

Evotec SE: Evotec Announces New Nomination to Board of Directors

2026-04-29T20:50:00.000Z - 13 days ago

Evotec SE: Evotec Announces New Nomination to Board of Directors

Evotec Announces New Nomination to Board of Directors

Apr 29, 2026, 4:45 PM EDT - 13 days ago

Evotec Announces New Nomination to Board of Directors

EVO

Evotec SE to Announce First Quarter 2026 Results on May 6, 2026

Apr 29, 2026, 1:50 AM EDT - 14 days ago

Evotec SE to Announce First Quarter 2026 Results on May 6, 2026

EVO

Evotec CFO Paul Hitchin to step down, Claire Hinshelwood to succeed

2026-04-24T09:10:45.000Z - 19 days ago

Evotec CFO Paul Hitchin to step down, Claire Hinshelwood to succeed

Evotec CFO Paul Hitchin Resigns; Names Claire Hinshelwood Replacement

2026-04-24T06:22:55.000Z - 19 days ago

Evotec CFO Paul Hitchin Resigns; Names Claire Hinshelwood Replacement

Evotec Announces Chief Financial Officer Transition

Apr 24, 2026, 1:50 AM EDT - 19 days ago

Evotec Announces Chief Financial Officer Transition

EVO

Evotec assumed with a Buy at H.C. Wainwright

2026-04-15T10:15:24.000Z - 4 weeks ago

Evotec assumed with a Buy at H.C. Wainwright

Evotec appoints Ingrid Muller as COO

2026-04-15T09:20:59.000Z - 4 weeks ago

Evotec appoints Ingrid Muller as COO

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

Apr 15, 2026, 1:50 AM EDT - 4 weeks ago

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

EVO

Evotec vows to further engage with investor MAK, who demanded change

Apr 7, 2026, 8:25 AM EDT - 5 weeks ago

Evotec vows to further engage with investor MAK, who demanded change

EVO

Evotec Nominates Dieter Weinand as Supervisory Board Chairman

Apr 7, 2026, 3:00 AM EDT - 5 weeks ago

Evotec Nominates Dieter Weinand as Supervisory Board Chairman

EVO

Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026

Apr 1, 2026, 5:35 AM EDT - 6 weeks ago

Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026

EVO

Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer

Apr 1, 2026, 1:50 AM EDT - 6 weeks ago

Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer

EVO

Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses

Mar 23, 2026, 3:10 AM EDT - 7 weeks ago

Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses

EVO

Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation

Mar 19, 2026, 2:50 AM EDT - 7 weeks ago

Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation

EVO

Evotec price target lowered to EUR 4.50 from EUR 6 at Deutsche Bank

2026-03-12T17:07:01.000Z - 2 months ago

Evotec price target lowered to EUR 4.50 from EUR 6 at Deutsche Bank

Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 11, 2026, 4:47 PM EDT - 2 months ago

Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

EVO

Evotec initiated with a Buy at Berenberg

2026-02-03T09:25:11.000Z - 3 months ago

Evotec initiated with a Buy at Berenberg

Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access

Jan 8, 2026, 1:50 AM EST - 4 months ago

Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access

EVO

Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations

Jan 2, 2026, 12:30 AM EST - 4 months ago

Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations

EVO

Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz

Dec 8, 2025, 1:20 AM EST - 5 months ago

Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz

EVO

Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome

Dec 4, 2025, 2:50 AM EST - 5 months ago

Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome

EVO

Evotec price target lowered to EUR 10 from EUR 11.20 at RBC Capital

2025-11-12T18:40:31.000Z - 6 months ago

Evotec price target lowered to EUR 10 from EUR 11.20 at RBC Capital

Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership

Nov 12, 2025, 2:00 AM EST - 6 months ago

Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership

EVO

Evotec announces up to EUR 3M share repurchase program

2025-11-06T14:46:32.000Z - 6 months ago

Evotec announces up to EUR 3M share repurchase program

Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities

Nov 5, 2025, 2:00 AM EST - 6 months ago

Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities

EVO

Evotec to sell Just – Evotec Biologics EU, license technology to Sandoz

2025-11-04T23:10:13.000Z - 6 months ago

Evotec to sell Just – Evotec Biologics EU, license technology to Sandoz

In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties

Nov 4, 2025, 4:30 PM EST - 6 months ago

In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties

EVO

Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025

Oct 29, 2025, 5:10 AM EDT - 7 months ago

Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025

EVO

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Oct 27, 2025, 2:50 AM EDT - 7 months ago

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

BMY EVO

Evotec price target lowered to EUR 11.20 from EUR 11.90 at RBC Capital

2025-09-03T18:10:35.000Z - 8 months ago

Evotec price target lowered to EUR 11.20 from EUR 11.90 at RBC Capital

Evotec price target lowered to $7 from $8 at H.C. Wainwright

2025-08-14T10:05:10.000Z - 9 months ago

Evotec price target lowered to $7 from $8 at H.C. Wainwright

Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution

Aug 13, 2025, 1:25 AM EDT - 9 months ago

Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution

EVO

Evotec SE to announce first half-year results 2025 on 13 August 2025

Aug 6, 2025, 4:15 AM EDT - 10 months ago

Evotec SE to announce first half-year results 2025 on 13 August 2025

EVO

Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site

Jul 30, 2025, 1:45 AM EDT - 10 months ago

Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site

EVO

Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site

Jul 30, 2025, 1:40 AM EDT - 10 months ago

Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site

EVO

Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix

Jul 21, 2025, 6:10 AM EDT - 10 months ago

Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix

EVO

Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance

Jul 21, 2025, 5:50 AM EDT - 10 months ago

Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance

EVO

Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury

Jun 25, 2025, 1:50 AM EDT - 11 months ago

Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury

EVO

Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments

May 7, 2025, 1:50 AM EDT - 1 year ago

Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments

EVO

Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment

May 6, 2025, 1:20 AM EDT - 1 year ago

Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment

EVO

Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025

Apr 29, 2025, 4:30 AM EDT - 1 year ago

Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025

EVO

Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb

Apr 24, 2025, 1:50 AM EDT - 1 year ago

Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb

EVO

Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results

Apr 17, 2025, 1:45 AM EDT - 1 year ago

Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results

EVO

Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025

Apr 10, 2025, 6:00 AM EDT - 1 year ago

Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025

EVO

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Mar 4, 2025, 1:45 AM EST - 1 year ago

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

BMY EVO

Evotec Announces Change in Management Board

Feb 26, 2025, 2:00 AM EST - 1 year ago

Evotec Announces Change in Management Board

EVO

Advancing Data Centric AI in Healthcare and Life Sciences - Elucidata Onboards Former CEO of Evotec and Ex-McKinsey Senior Partner

Feb 19, 2025, 7:55 AM EST - 1 year ago

Advancing Data Centric AI in Healthcare and Life Sciences - Elucidata Onboards Former CEO of Evotec and Ex-McKinsey Senior Partner

EVO

Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Jan 22, 2025, 2:00 AM EST - 1 year ago

Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

EVO

Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Dec 11, 2024, 2:00 AM EST - 1 year ago

Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

EVO

Comment on Withdrawn Non-Binding Offer

Nov 22, 2024, 11:15 AM EST - 1 year ago

Comment on Withdrawn Non-Binding Offer

EVO

Halozyme withdraws $2.1 bln buyout offer for Evotec

Nov 22, 2024, 8:55 AM EST - 1 year ago

Halozyme withdraws $2.1 bln buyout offer for Evotec

EVO HALO

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

Nov 22, 2024, 8:35 AM EST - 1 year ago

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

EVO HALO

Halozyme CEO: Evotec Is Poised for Growth

Nov 18, 2024, 4:00 PM EST - 1 year ago

Halozyme CEO: Evotec Is Poised for Growth

EVO HALO

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

Nov 18, 2024, 7:00 AM EST - 1 year ago

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

EVO HALO

Comment on Media Report

Nov 14, 2024, 5:30 PM EST - 1 year ago

Comment on Media Report

EVO

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

Nov 14, 2024, 4:15 PM EST - 1 year ago

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

EVO HALO

Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports

Nov 14, 2024, 4:09 PM EST - 1 year ago

Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports

EVO HALO

Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

Nov 6, 2024, 1:20 AM EST - 1 year ago

Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

EVO

peloswing
peloswing May. 13 at 1:27 PM
$EVO -12% in pre-market following €116.1 Million Convertible Bond headline 🔻
0 · Reply
KOWALSK1
KOWALSK1 Apr. 20 at 6:56 PM
$EVO
0 · Reply
AnonMav
AnonMav Apr. 17 at 3:11 PM
$EVO Reclaim story begins
0 · Reply
KOWALSK1
KOWALSK1 Apr. 16 at 10:50 PM
$EVO
0 · Reply
BioTuesdays
BioTuesdays Apr. 15 at 2:53 PM
$EVO has appointed Dr. Ingrid Müller as Chief Operating Officer (COO), effective May 1, 2026. https://biotuesdays.com/2026/04/15/dr-ingrid-muller-joins-evotec-as-coo/
0 · Reply
LewisDaKat
LewisDaKat Apr. 15 at 10:31 AM
$EVO Evotec Appoints Dr. Ingrid M ller as Chief Operating Officer https://marketwirenews.com/stock/evo/news/evotec-appoints-dr-ingrid-m-xfc-ller-as-chief-operat-6497978197933043.html?utm_source=stocktwits
0 · Reply
AnonMav
AnonMav Apr. 14 at 9:56 AM
$EVO 1st sign of life 👍
0 · Reply
AnonMav
AnonMav Apr. 12 at 1:47 AM
$EVO Six levels painted. You're at the bottom of the structure, grinding on purple. Below $2.52 = pain. Above $2.95 = first sign of life. Everything above $3.28 is a reclaim story. Don't hold your breath but keep it on the radar. 🤙 https://share.trendspider.com/chart/EVO/94993v3s3vk?_go=anonmav
0 · Reply
investmentstarry
investmentstarry Apr. 2 at 8:45 AM
$EVO — Capital Allocation Update 💡 Board proposes ZERO dividend for 2025 Company pivoting toward share buybacks I like this move — better capital allocation while valuation remains low (PE ~10x)
0 · Reply
BioTuesdays
BioTuesdays Apr. 1 at 2:55 PM
$EVO has appointed Dr. Ashiq H. Khan as EVP global head, chief commercial officer (CCO). https://biotuesdays.com/2026/04/01/evotec-appoints-dr-ashiq-h-khan-as-cco/
0 · Reply
KOWALSK1
KOWALSK1 Mar. 24 at 11:54 AM
$EVO Evotec ag ✅️ BUY ZONE 2.39 to 2.38 ✋️ RISK BELOW 2.21 🎯 PT. 2.50 2.59 2.70 2.97 3.12 + UP Follow for more
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 4:43 PM
$EVO RSI: 21.96, MACD: -0.2852 Vol: 0.44, MA20: 3.01, MA50: 3.37 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 12:33 PM
$EVO RSI: 46.05, MACD: 0.0154 Vol: 0.11, MA20: 3.60, MA50: 3.41 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 16 at 6:41 PM
$EVO Current Stock Price: $3.52
0 · Reply
ShadowGale
ShadowGale Feb. 4 at 2:08 PM
$EVO is a payment technology and services company; it operates in a consolidating industry and must invest to keep pace with technological change.
0 · Reply
topstockalerts
topstockalerts Feb. 3 at 2:59 PM
$EVO Looks like it wants higher prices. Buyers keep stepping in. This trend is still alive 📈.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 23 at 1:24 PM
$EVO RSI: 66.89, MACD: 0.1133 Vol: 0.26, MA20: 3.42, MA50: 3.20 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 5 at 11:49 PM
$EVO Current Stock Price: $3.19
0 · Reply
CustomsCap
CustomsCap Dec. 25 at 1:09 PM
$EVO Volatility reflects tension between long‑term potential and near‑term uncertainty. Competitive dynamics are compressing the timeline for visible traction. Aligned incentives and governance can stabilize expectations. Risk remains manageable if management converts plans into consistent outputs.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 24 at 3:46 PM
$EVO Current Stock Price: $3.10
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 19 at 2:21 PM
$EVO Current Stock Price: $2.93
0 · Reply
Alarusso68
Alarusso68 Dec. 8 at 4:09 PM
$BNB.X This week we released the new tier system and activated token-gated access for the $EVO bot. Next, we’ll be working on the $EVO Credit System, where users will earn $EVO credits based on their holdings. Overall, it was a solid week, the market is rising again, and we’re gearing up to become the next major on-chain utility.,, Stay tuned; there’s much more coming Our vision is simple: transform raw blockchain data into intelligence that empowers smarter, safer, and more confident decisions. This is where innovation meets precision. This is Envion AI crypto on Ethereum. Buy while its still low!! C/A 0x61577e532d850dc7d6a8a81bcb945c01ba33a457
0 · Reply